List of Belsomra drug patents
Belsomra is owned by Merck Sharp Dohme.
Belsomra contains Suvorexant.
Belsomra has a total of 2 drug patents out of which 0 drug patents have expired.
Belsomra was authorised for market use on 13 August, 2014.
Belsomra is available in tablet;oral dosage forms.
Belsomra can be used as treatment of insomnia.
The generics of Belsomra are possible to be released after 29 May, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic